ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
13 mars 2023 08h00 HE
|
Oryzon Genomics, S.A.
A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) --...
ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
22 févr. 2023 08h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
17 févr. 2023 10h08 HE
|
Oryzon Genomics, S.A.
Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 ...
ORYZON to Give Updates on Corporate Progress in February-March
06 févr. 2023 08h00 HE
|
Oryzon Genomics, S.A.
BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer Epigenetics Institute Symposium: From Genes to Chromatin...
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas
18 janv. 2023 08h12 HE
|
Oryzon Genomics, S.A.
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a broad collaboration with The Cancer Epigenetics...
ORYZON to Give Updates on Corporate Progress in January
05 janv. 2023 08h00 HE
|
Oryzon Genomics, S.A.
6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2023 MADRID, Spain and...
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
16 déc. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Eurostars-3 collaborative project with Danish institutions ImProTher and University of Copenhagen Global budget of 1.4 million euros; Oryzon to receive up to 400,000 euros Project will assess the...
ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022
12 déc. 2022 12h24 HE
|
Oryzon Genomics, S.A.
Robust, rapid and durable efficacy - ORR 81%, of which 64% are CR/CRi68% of CR/CRi lasting more than 6 monthsLongest remission + 3 yearsIadademstat and azacitidine combination shows a good safety...
ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)
09 nov. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Collaborative study with Fox Chase Cancer Center (FCCC)Oryzon and FCCC will collaborate to assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs MADRID and SPAIN and...
ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference
07 nov. 2022 08h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...